Avantor (AVTR)
(Real Time Quote from BATS)
$20.82 USD
-0.19 (-0.90%)
Updated Jul 5, 2024 10:22 AM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Brokerage Reports
Avantor, Inc. [AVTR]
Reports for Purchase
Showing records 101 - 120 ( 134 total )
Company: Avantor, Inc.
Industry: Medical Services
Bioproduction: FDA Advisory Committee COVID-19 Vaccine Hearing Highlights
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Life Science Tools: ''De-Icing'' the COVID-19 Vaccine with Timeline, Production Pictures, Tool Opportunity
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Transfer Coverage; Upgrade to Overweight; Life Science Tailwinds for Improved 3.0 Version
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Medical Products 2H20 Outlook: It?s Tricky to Rock a Rhyme That?s Right on Time
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Healthcare: Sorting Through an Unusual Circumstance
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department